Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
First Claim
Patent Images
1. An in vivo gelling pharmaceutical pre-formulation, comprising:
- (a) one or more multi-ARM nucleophilic PEG monomers, wherein the multi-ARM PEG nucleophilic monomers comprise a polyol core, wherein the polyol core is selected from the group consisting of
6 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are biocompatible hydrogel polymers capable of gelling in vivo comprising a therapeutic agent such as a protein or other biomolecule and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure and achieving a controlled delivery.
87 Citations
18 Claims
-
1. An in vivo gelling pharmaceutical pre-formulation, comprising:
(a) one or more multi-ARM nucleophilic PEG monomers, wherein the multi-ARM PEG nucleophilic monomers comprise a polyol core, wherein the polyol core is selected from the group consisting of - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
12. A biocompatible hydrogel polymer made by mixing:
(a) one or more multi-ARM nucleophilic PEG monomers, wherein the multi-ARM PEG nucleophilic monomers comprise a polyol core, wherein the polyol core is selected from the group consisting of - View Dependent Claims (13, 14, 15, 16, 17, 18)
Specification